2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170032
    Oxotremorine 70-22-4 98%
    Oxotremorine is an agonist for mAChR, that activates M1 and M3 acetylcholine receptors. Oxotremorine exhibits nicotine-like effects in drug discrimination experiments in macaques.
    Oxotremorine
  • HY-170033
    3-Carboxamidonaltrexone 421552-35-4 98%
    3-Carboxamidonaltrexone (example 32) is a opioid receptor binding compound with Ki values of 1.9 nM, 110 nM, and 22 nM for μ-opioid receptor, δ-opioid receptor, and K-opioid receptor, respectively.
    3-Carboxamidonaltrexone
  • HY-170051
    4-Methyl-α-isopropylaminovalerophenone hydrochloride 18296-68-9 98%
    4-Methyl-α-isopropylaminovalerophenone hydrochloride is a drug derivative.
    4-Methyl-α-isopropylaminovalerophenone hydrochloride
  • HY-170052
    α-Isopropylaminohexanophenone hydrochloride 18296-61-2 98%
    α-Isopropylaminohexanophenone hydrochloride is a drug derivative.
    α-Isopropylaminohexanophenone hydrochloride
  • HY-170053
    4-Hydroxy MPT 763035-03-6 98%
    4-Hydroxy MPT (4-OH-MPT), a serotonergic hallucinogen, is a 5-HT2A and 5-HT2B receptors agonist with EC50 values of 3.82 nM and 3.4 nM, respectively.
    4-Hydroxy MPT
  • HY-17020S
    Miglustat-d9 1883545-56-9 98%
    Miglustat-d9 is the deuterium labeled Miglustat. Miglustat (N-Butyldeoxynojirimycin) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
    Miglustat-d9
  • HY-170236
    nNOS-IN-5 2945955-27-9 98%
    nNOS-IN-5 (Compound 9) is a potent human neuronal NOS (nNOS) inhibitor (Ki = 22 nM). nNOS-IN-5 exhibits excellent selectivity, with a 900-fold preference for human nNOS over human endothelial NOS (eNOS). nNOS-IN-5 can be used for neurodegenerative diseases study, such as Alzheimer's disease and Parkinson’s disease.
    nNOS-IN-5
  • HY-170310
    AP-238 140924-11-4 98%
    AP-238 is a a new synthetic opioid (NSO), and acts as an agonist for μ-opioid receptor (MOR) with an EC50 of 248 nM. AP-238 exhibits analgesic activity.
    AP-238
  • HY-170325
    17alpha-Hydroxywithanolide D 98%
    17alpha-Hydroxywithanolide D is the allosteric modulator for NMDA receptor with an IC50 of 44.24 nM. 17alpha-Hydroxywithanolide D exhibits neuroprotective activity and can be used in research of Alzheimer's disease disease.
    17alpha-Hydroxywithanolide D
  • HY-17032A
    Indeloxazine hydrochloride 65043-22-3 98%
    Indeloxazine hydrochloride is a 5-HT receptor and norepinephrine (NE) reuptake inhibitor. Indeloxazine hydrochloride is an antidepressant and cerebral activator.
    Indeloxazine hydrochloride
  • HY-17037S
    Pirenzepine-d8 1189944-02-2 98%
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-170381
    α-syn aggregation inhibitor-1 98%
    α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y.
    α-syn aggregation inhibitor-1
  • HY-170389
    BChE-IN-39 98%
    BChE-IN-39 (Compound 7c) is a selective inhibitor for butyrylcholinesterase (BChE) with an IC50 of 0.08 μM (IC50=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein.
    BChE-IN-39
  • HY-170409
    BNN27 1195795-81-3 98%
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.
    BNN27
  • HY-170417
    hAChE/hBuChE/GSK-3β-IN-1 98%
    hAChE/hBuChE/GSK-3β-IN-1 (Compound 6c) is a BBB-penetrable and multi-target anti-Alzheimer's disease compound. hAChE/hBuChE/GSK-3β-IN-1 is the inhibitors of hAChE (IC50: 28.88 nM), hBuChE (IC50: 131.90 nM) and GSK-3β (IC50: 51.42 nM). hAChE/hBuChE/GSK-3β-IN-1 is the tau and Aβ protein aggregation inhibitors.
    hAChE/hBuChE/GSK-3β-IN-1
  • HY-170437
    MOR modulator-1 2976336-81-7 98%
    MOR modulator-1 (compound 6) is a potent and selective μ opioid receptor (MOR) modulator. MOR modulator-1 exhibits improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT (6α-configuration). MOR modulator-1 links with carboxamido linker μ, δ, γ with Kis of 0.25, 41.1, 1.30 nM, respectively[1]
    MOR modulator-1
  • HY-170444
    ADS1017 98%
    ADS1017 is the antagonist for histamine receptor and muscarinic receptor, that exhibits good affinities to hH3R, hH4R, hM2R and hM4R with pKi of 6.8, 5.5, 7.4 and 7.2. ADS1017 exhibits analgesic and anti-allodynic efficacy in mice Capsaicin (HY-10448)-or Oxaliplatin (HY-17371)-induced pain models.
    ADS1017
  • HY-170475
    5-MeO-MET 16977-53-0 98%
    5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a 5-methoxytryptamines compound. 5-MeO-MET is the agonist of 5-HT1A and 5-HT2A. 5-MeO-MET can inhibit the movement of mice and has a sedative effect.
    5-MeO-MET
  • HY-170484
    KAI-11101 98%
    KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel (HY-B0015)-induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property.
    KAI-11101
  • HY-170487
    MAO-B-IN-38 98%
    MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases.
    MAO-B-IN-38
Cat. No. Product Name / Synonyms Application Reactivity